Forxiga: Advanced SGLT2 Inhibitor for Glycemic Control and Cardiovascular Protection
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 42 | $3.11 | $130.72 (0%) | 🛒 Add to cart |
| 56 | $3.06 | $174.29 $171.14 (2%) | 🛒 Add to cart |
| 70 | $3.03 | $217.87 $212.42 (2%) | 🛒 Add to cart |
| 84 | $3.00 | $261.44 $251.98 (4%) | 🛒 Add to cart |
| 98 | $2.98
Best per pill | $305.01 $292.40 (4%) | 🛒 Add to cart |
Synonyms | |||
Forxiga (dapagliflozin) is a prescription medication belonging to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, designed for the management of type 2 diabetes mellitus in adults. It functions by promoting the excretion of excess glucose through the urine, thereby lowering blood sugar levels. Beyond glycemic control, Forxiga has demonstrated significant cardiovascular and renal benefits in appropriate patient populations, reducing the risk of hospitalization for heart failure and delaying the progression of kidney disease. Its dual-action mechanism offers a comprehensive approach to diabetes management, positioning it as a cornerstone therapy in modern treatment algorithms.
Features
- Active ingredient: dapagliflozin (5 mg or 10 mg film-coated tablets)
- Pharmacologic class: sodium-glucose cotransporter 2 (SGLT2) inhibitor
- Administration: oral, once daily
- Excipients: lactose monohydrate, microcrystalline cellulose, and other non-active components
- Packaging: blister packs of 14, 28, or 56 tablets
- Manufacturer: AstraZeneca
- Regulatory approvals: FDA, EMA, and other major health authorities worldwide
Benefits
- Achieves significant and sustained reductions in HbA1c levels
- Lowers the risk of major adverse cardiovascular events, including heart failure hospitalization
- Provides weight loss and modest blood pressure reduction as ancillary benefits
- Reduces the progression of kidney disease in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
- Offers a once-daily dosing regimen for improved adherence
- Functions independently of insulin secretion or sensitivity
Common use
Forxiga is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Additionally, it is used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
Dosage and direction
The recommended starting dose is 5 mg or 10 mg orally once daily, taken in the morning with or without food. Dosage may be adjusted based on therapeutic response, tolerability, and renal function. For patients with an eGFR below 45 mL/min/1.73m², use for glycemic control is not recommended, though it may be continued for cardiovascular and renal benefits if already tolerated. Tablets should be swallowed whole with a glass of water; they should not be split, crushed, or chewed.
Precautions
- Assess renal function before initiation and periodically during treatment
- Monitor for signs and symptoms of volume depletion, particularly in elderly patients, those on diuretics, or with renal impairment
- Evaluate for genital mycotic infections; maintain proper hygiene to reduce risk
- Consider temporary discontinuation prior to scheduled surgery or during periods of prolonged fasting
- Monitor for ketoacidosis, even in the presence of normal or mildly elevated blood glucose levels
- Not recommended during the second and third trimesters of pregnancy
- Use with caution in patients with history of pancreatitis
Contraindications
- History of serious hypersensitivity reaction to dapagliflozin or any excipients
- Severe renal impairment (eGFR <30 mL/min/1.73m²), end-stage renal disease, or patients on dialysis
- Type 1 diabetes mellitus or diabetic ketoacidosis
- Concomitant use with other SGLT2 inhibitors
- Pregnancy during the second and third trimesters
- Breastfeeding
Possible side effects
Common (≥1/100 to <1/10):
- Genital mycotic infections
- Urinary tract infections
- Polyuria
- Nocturia
- Increased urination
- Thirst
Uncommon (≥1/1,000 to <1/100):
- Volume depletion
- Constipation
- Dyslipidemia
- Back pain
- Rash
Rare (≥1/10,000 to <1/1,000):
- Ketoacidosis
- Necrotizing fasciitis of the perineum (Fournier’s gangrene)
- Acute kidney injury
- Hypersensitivity reactions
- Increased hematocrit
Drug interaction
- Diuretics: increased risk of volume depletion
- Insulin or insulin secretagogues: increased risk of hypoglycemia; dose adjustment may be required
- Drugs that reduce renal function: may diminish efficacy
- Positive urine glucose tests: may occur due to mechanism of action
- Lithium: may decrease lithium concentrations; monitor levels
- UGT1A9 inducers: may decrease dapagliflozin exposure
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If remembered the next day, skip the missed dose and resume the regular dosing schedule. Do not take a double dose to make up for a missed dose.
Overdose
In case of overdose, symptomatic and supportive measures are recommended. Dapagliflozin can be removed by hemodialysis (approximately 30% removal over 4 hours). Monitor for dehydration, hypoglycemia, and electrolyte abnormalities. Contact poison control or seek immediate medical attention.
Storage
Store at room temperature (15–30°C) in the original packaging to protect from moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Always consult a healthcare provider for diagnosis, treatment decisions, and personalized medical guidance. Do not initiate or discontinue medication without consulting your physician.
Reviews
Clinical trials and real-world evidence consistently demonstrate Forxiga’s efficacy in glycemic control, cardiovascular risk reduction, and renal protection. The DAPA-HF and DAPA-CKD trials established its role in heart failure and chronic kidney disease management, respectively. Patients report improved quality of life due to stable glucose levels and weight management benefits. Healthcare providers appreciate its cardiorenal protective properties and once-daily dosing convenience. Long-term studies confirm a favorable benefit-risk profile in appropriate patient populations.